ArticleResearch square2025
BRD2 impedes iPSC reprogramming by regulating lipogenesis and matrisome.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Induction of human pluripotent stem cells (HiPSCs) from somatic cells encounters significant barriers, which remain poorly understood. Lipids are fundamental cellular molecules with many essential roles. However, lipid roles in reprogramming are unknown. Here, we prove that BRD2 is a barrier to HiPSC reprogramming by suppressing lipogenesis and maintaining the somatic transcriptional program, particularly the somatic matrisome program. Strikingly, the acetylation epigenetic reader BRD2 unorthodoxically suppressed gene expression of lipogenesis in the reprogramming cells. The two rate-limiting enzymes of lipogenesis, SCD and HMGCR, enhanced iPSC reprogramming while lipid supplements enhanced it. Interestingly, the BRD2 ET tail suppressed reprogramming and the lipogenesis transcriptional program but positively regulated matrisome program. In line with its transcriptional suppression of lipogenesis, BRD2 binds to genes of lipogenesis and negatively regulates their H3K27Ac status. These discoveries advance our knowledge of HiPSC reprogramming by revealing the opposite BRD2 regulatory roles on matrisome and lipogenesis in promoting reprogramming.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.